Emergency Contraception

FSRH CEU Statement: Combined oral contraceptive interference with the ability of ulipristal acetate to delay ovulation: A prospective cohort study - August 2018

28 August 2018

Evidence from new study supports the existing FSRH recommendation that commencement of hormonal contraception should be delayed for 5 days after UPA-EC. Published 28/8/2018.

Please read this guidance document in conjunction with any relevant clinical statements for this topic.
These can be found by visiting the Clinical Statements section.

FSRH CEU response to European Medicines Agency recommendations regarding use of ulipristal acetate for management of uterine fibroids

12 February 2018

The European Medicines Agency (EMA) is currently reviewing the safety of use of Esmya® (ulipristal acetate) for management of uterine fibroids. This review follows reports of a very small number of cases worldwide of serious liver injury in women using Esmya. Until the review process is complete, temporary restrictions have been placed on commencing treatment with Esmya and guidelines for monitoring liver function in women already taking Esmya have been introduced. The EMA recommendations are available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/02/news_detail_002902.jsp&mid=WC0b01ac058004d5c1

This document is up-to-date